Standard
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re : results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). / Wiegel, Thomas; Albers, Peter; Bartkowiak, Detlef; Bussar-Maatz, Roswitha; Härter, Martin; Kristiansen, Glen; Martus, Peter; Wellek, Stefan; Schmidberger, Heinz; Grozinger, Klaus; Renner, Peter; Schneider, Fried; Burmester, Martin; Stöckle, Michael.
In:
J CANCER RES CLIN, Vol. 147, No. 4, 04.2021, p. 1273-1274.
Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
Wiegel, T, Albers, P, Bartkowiak, D, Bussar-Maatz, R
, Härter, M, Kristiansen, G, Martus, P, Wellek, S, Schmidberger, H, Grozinger, K, Renner, P, Schneider, F, Burmester, M & Stöckle, M 2021, '
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)',
J CANCER RES CLIN, vol. 147, no. 4, pp. 1273-1274.
https://doi.org/10.1007/s00432-021-03549-yAPA
Wiegel, T., Albers, P., Bartkowiak, D., Bussar-Maatz, R.
, Härter, M., Kristiansen, G., Martus, P., Wellek, S., Schmidberger, H., Grozinger, K., Renner, P., Schneider, F., Burmester, M., & Stöckle, M. (2021).
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J CANCER RES CLIN,
147(4), 1273-1274.
https://doi.org/10.1007/s00432-021-03549-yVancouver
Bibtex
@article{df3d262006f74a428016a78af41e3334,
title = "Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)",
author = "Thomas Wiegel and Peter Albers and Detlef Bartkowiak and Roswitha Bussar-Maatz and Martin H{\"a}rter and Glen Kristiansen and Peter Martus and Stefan Wellek and Heinz Schmidberger and Klaus Grozinger and Peter Renner and Fried Schneider and Martin Burmester and Michael St{\"o}ckle",
year = "2021",
month = apr,
doi = "10.1007/s00432-021-03549-y",
language = "English",
volume = "147",
pages = "1273--1274",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "4",
}
RIS
TY - JOUR
T1 - Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re
T2 - results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
AU - Wiegel, Thomas
AU - Albers, Peter
AU - Bartkowiak, Detlef
AU - Bussar-Maatz, Roswitha
AU - Härter, Martin
AU - Kristiansen, Glen
AU - Martus, Peter
AU - Wellek, Stefan
AU - Schmidberger, Heinz
AU - Grozinger, Klaus
AU - Renner, Peter
AU - Schneider, Fried
AU - Burmester, Martin
AU - Stöckle, Michael
PY - 2021/4
Y1 - 2021/4
U2 - 10.1007/s00432-021-03549-y
DO - 10.1007/s00432-021-03549-y
M3 - Other (editorial matter etc.)
C2 - 33625578
VL - 147
SP - 1273
EP - 1274
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 4
ER -
